HK Stock Market Move | MP CARDIOFLOW-B (02160) rose nearly 5%, with expected losses in the first half not exceeding $25 million. The global arrhythmia management business continues to grow steadily.

MP CARDIOFLOW-B (02160) rose nearly 5%, and as of the time of reporting, it had increased by 4.72%, reaching HK$1.33, with a transaction volume of HK$2.302 million. In terms of news, Micron Heart announced that the group will complete the acquisition of the cardiac rhythm management business on December 19, 2025, and this business will be fully consolidated into the group's financial statements for the six months ending June 30, 2026, for the first time. According to the latest available information, it is expected that the reported period will generate revenue of no less than US$153 million, with a net loss not exceeding US$25 million. During the reporting period, the group's global cardiac rhythm management business continued to grow steadily, with the number of pacemaker implants in the Chinese market achieving double-digit growth; the company's VitaFlow Liberty transcatheter aortic valve replacement system has accelerated its commercialization in CE-certified regions, with simultaneous registration and sales scaling up in emerging countries, achieving over 350% growth in the number of implants in more than 40 countries outside of China compared to the same period last year, and setting a record of over 250 implants in a single month.